Evotec's Cost-Cutting Race Against a Deepening Order Slump

Evotec shares trade at EUR 3.03, just above a 52-week low, after a 44% YTD decline and a reaffirmed 2026 guidance cut.

Evotec shares changed hands at EUR 3.03 on Friday, settling just 1.9% above the 52-week low of EUR 2.97 touched during the previous session. The German biotech has now surrendered 44% of its value since the start of the year, with 21% of that decline coming in the last 30 days alone. A 14-day relative strength index of 28.9 places the stock firmly in oversold territory — a technical signal that, on its own, offers little comfort given the fundamental strain weighing on the company.

A Guidance Cut That Still Reverberates

Roughly two weeks ago, Evotec reaffirmed the sharply reduced 2026 outlook it had first issued in July. Revenue is now projected at EUR 570 million to EUR 610 million, down from an original target of EUR 700 million to EUR 780 million. Adjusted EBITDA is expected to land between a loss of EUR 70 million and EUR 105 million — a stark reversal from the previously indicated positive figure of up to EUR 40 million.

Since that confirmation, the stock has shed another 9.9%. Management attributes the deterioration to postponed milestone payments and delayed partnership agreements, a pattern that has persisted throughout the current fiscal year.

The half-year figures lay bare the extent of the damage. Revenue fell 19.2% year on year to EUR 300.1 million, while adjusted EBITDA swung to a loss of EUR 42.7 million from a deficit of just EUR 1.9 million in the prior-year period. Both core segments felt the pinch: Discovery & Preclinical Development posted a 15.8% revenue decline in the second quarter to EUR 108.1 million, and Just-Evotec Biologics dropped 17.4% to EUR 35.4 million.

Horizon Restructuring as a Counterweight

Against this grim backdrop, Evotec is pressing ahead with the "Horizon" restructuring programme unveiled in March. The plan calls for shrinking the company's global footprint from 19 sites to 10, targeting structural savings of roughly EUR 75 million per year by the end of 2027. For the current year, management expects to capture 20% to 30% of that total.

One bright spot: net sales in the Discovery segment, excluding strategic partnerships, climbed 28% in the first half. That suggests the underlying operating business remains intact despite the turbulence in milestone income.

Fresh Partnerships, Familiar Market Response

Evotec has kept its deal machine running. On 9 September, Evotec Biologics announced the launch of a Phase I clinical trial for JST-018, an antibody programme targeting orthopoxviruses, conducted under a collaboration with the U.S. Department of War. A week earlier, on 2 September, the company kicked off a research partnership with Plectonic Biotech to develop a T-cell engager strategy against solid tumours, combining Plectonic's LOGIBODY technology with Evotec's BiTco platform.

Those announcements followed an AI-driven collaboration with Odyssey Therapeutics, disclosed roughly a month ago, focused on developing new active substances against autoimmune and inflammatory diseases. Financial terms of that arrangement were not disclosed. Yet the scientific momentum has done nothing to halt the slide — the stock has lost 12.3% since the Odyssey deal became public.

Governance Noise Adds to the Din

Alongside the pipeline news, a flurry of capital-markets filings has drawn attention. Evotec published voting rights notifications concerning stake changes at JPMorgan Chase & Co. and The Goldman Sachs Group. Such disclosures are purely regulatory events rather than corporate news, but they underscore the heightened market scrutiny surrounding the stock.

Investor confidence has also been tested by the departure of supervisory board member Camilla Macapili Languille, effective 7 August. Her exit coincided with the release of the half-year results, in which Evotec confirmed its already-lowered full-year 2026 earnings guidance.

The Question That Matters

The central issue for shareholders is whether Horizon's cost reductions will take hold faster than the order slowdown erodes the business. Trading 38% below its 200-day moving average with a market capitalisation of EUR 557.61 million, the share price already reflects considerable scepticism.

Until Evotec can point to new, concrete contract wins, investor trust is likely to remain brittle — no matter how oversold the technical picture may look.